China Food and Drug Administration ("CFDA”) issued the Opinions on Encouraging the Prioritised Evaluation and Approval for Drug Innovations (“Opinions”) on 28 December 2017. The Opinions set out the type of drugs that may enjoy the prioritised evaluation regime, which includes certain drugs of significant clinical value or great clinical advantage in the treatment of certain diseases. The Opinions also provide the proceedings and requirements of the prioritised evaluation.